122 related articles for article (PubMed ID: 37828859)
1. Dissolving Fusion Oncoprotein Condensates to Reverse Aberrant Gene Expression.
Shirnekhi HK; Chandra B; Kriwacki RW
Cancer Res; 2023 Oct; 83(20):3324-3326. PubMed ID: 37828859
[TBL] [Abstract][Full Text] [Related]
2. Dissolution of oncofusion transcription factor condensates for cancer therapy.
Wang Y; Yu C; Pei G; Jia W; Li T; Li P
Nat Chem Biol; 2023 Oct; 19(10):1223-1234. PubMed ID: 37400539
[TBL] [Abstract][Full Text] [Related]
3. Single-molecule Imaging of EWS-FLI1 Condensates Assembling on DNA.
Zuo L; Ding J; Qi Z
J Vis Exp; 2021 Sep; (175):. PubMed ID: 34570101
[TBL] [Abstract][Full Text] [Related]
4. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
5. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
6. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
7. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
8. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
9. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
10. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
11. Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.
Ryan JJ; Sprunger ML; Holthaus K; Shorter J; Jackrel ME
J Biol Chem; 2019 Jul; 294(29):11286-11296. PubMed ID: 31171724
[TBL] [Abstract][Full Text] [Related]
12. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.
Gao Y; He XY; Wu XS; Huang YH; Toneyan S; Ha T; Ipsaro JJ; Koo PK; Joshua-Tor L; Bailey KM; Egeblad M; Vakoc CR
Nat Cell Biol; 2023 Feb; 25(2):298-308. PubMed ID: 36658219
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
14. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
15. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
[TBL] [Abstract][Full Text] [Related]
16. ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion.
Saulnier O; Guedri-Idjouadiene K; Aynaud MM; Chakraborty A; Bruyr J; Pineau J; O'Grady T; Mirabeau O; Grossetête S; Galvan B; Claes M; Al Oula Hassoun Z; Sadacca B; Laud K; Zaïdi S; Surdez D; Baulande S; Rambout X; Tirode F; Dutertre M; Delattre O; Dequiedt F
Nucleic Acids Res; 2021 May; 49(9):5038-5056. PubMed ID: 34009296
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
[TBL] [Abstract][Full Text] [Related]
18. The
Johnson CN; Xu X; Holloway SP; Libich DS
Biomol NMR Assign; 2022 Apr; 16(1):67-73. PubMed ID: 34994941
[TBL] [Abstract][Full Text] [Related]
19. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
